An observational study in Pancreatic Cancer, Adult, sponsored by Beth Israel Deaconess Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Beth Israel Deaconess Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardize study population, screening methodology, and study outcomes.
Methods The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of pancreas cancer screening in high-risk individuals. High-risk patients who are undergoing pancreatic cancer screening in accordance with national guidelines at participating study centers will be eligible for the study. Information regarding patient characteristics, findings at screening examination, and patient outcomes will be collected.
Primary Outcome (Primary Aim):
To identify the proportion of patients who meet International Cancer of the Pancreas Screening Consortium screening criteria 3rd update (CAPS Jan 2020), or more updated national guidelines, who are found at the screening to have high-risk pancreatic lesions amenable to treatment (definition of "high-risk lesions amenable to treatment" is provided under the section on study outcomes).
Secondary outcomes (Secondary Aims) will include (details are provided under the section on study outcomes):
Screening and patient follow-up will be performed at individual study centers per standard clinical practice. Patient characteristics, screening performed and screening results, clinical outcome data will be collected by individual study centers. This data will be stored and analyzed at central study REDCap located at Beth Israel Deaconess Medical Center (BIDMC)
25 studies on the registry are indexed under Pancreatic cancer, adult; 18 are open to participants now.
Browse Pancreatic cancer, adult studies →Beth Israel Deaconess Medical Center is the lead sponsor of 570 studies on the registry; 80 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 62 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Any patient who meets the eligibility criteria exposed above based on CAPS3 or updated national pancreatic screening guidelines criteria at BIDMC and collaboration centers part of the study in the time frame of 2020 to 2027 (which is the end of enrollment)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria 1-3 are indications for pancreatic cancer screening as defined by the CAPS3 guidelines or updated national pancreatic cancer screening guidelines. Patients who do not meet these guidelines but are undergoing pancreatic cancer screening at the discretion of their treating physician at participating study centers will also be included in the study. Based upon the indication for screening, patients will be categorized as either meeting CAPS3 screening criteria, or not meeting CAPS3 screening criteria.
Familial Pancreatic cancer kindred. This is defined as family history of pancreas cancer that meet the criteria listed below.
Patients with genetic susceptibility to pancreas cancer
Screening is usually initiated at age 45 years or 10 years younger than the youngest family member with pancreatic cancer.
Hereditary Breast and Ovarian Cancer syndrome: diagnosed using clinical criteria or deleterious Breast Cancer gene 1 (BRCA1), Breast Cancer gene 2 (BRCA2), Partner and Localizer of BRCA2 (PALB2). The usual indication for screening is:
Lynch syndrome or Ataxia Telangiectasia Mutated (ATM) mutations with at least one affected first-degree relative (FDR). Lynch syndrome could be diagnosed either by using clinical criteria or Mutator L homolog 1 (MLH1), Mutator S homolog 2 (MSH2), Mutator S homolog 6 (MSH6), Postmeiotic Segregation Increased, S. Cerevisiae, 2 (PMS2) or EPCAM mutation.
Screening to be initiated at age 45 or 10 years younger than the youngest family member with pancreatic cancer.
Exclusion Criteria:
Patients that meet the eligibility criteria based on CAPS3 or updated national pancreatic cancer screening guidelines
Other: Screening for pancreatic cancer
Screening for pancreatic cancer using EUS or MRI
Proportion of screening patients found to have high-risk pancreatic lesions amenable to treatment
Proportion of patients who meet CAPS 3 or updated national screening guidelines criteria who are found at screening to have high-risk pancreatic lesions amenable to treatment. These are defined as the following: 1. Lesions with high-grade dysplasia (HGD) 2. High-grade pancreatic intraepithelial neoplasia (PanIN) 3. Resectable or borderline resectable pancreatic cancer. Pancreatic cancers that were staged T1-3, N0-2, and M0 designated as resectable or borderline resectable. Cancers that were staged as T4 or M1 were considered locally advanced or metastatic and therefore designated as unresectable 4. Main duct intra-ductal papillary mucinous neoplasm (IPMN).This will be defined per Fukuoko guidelines as dilation of main pancreatic duct ≥ 5 mm, after duct dilation due to other causes have been excluded. 5. Branch-duct IPMN with "worrisome features". 6. Neuroendocrine tumor ≥ 2 cm.
Time frame: From year 1 to year 12 (until the end of at least 5 years follow up in 2032), according to the standard of care designated by GI team.
Proportion of screening patients found to have high-risk pancreatic lesions
Proportion of patients who meet CAPS screening eligibility criteria, who are found at screening to have high-risk pancreatic lesions amenable to treatment
Time frame: From year 1 screening to year 12 (end of at least 5 years follow up in 2032) screening (annually)
Proportion of screening patients found to have low or moderate-risk pancreatic lesions by screening
Proportion of patients undergoing pancreatic cancer screening who are found to have low or moderate-risk pancreatic lesions. Low or moderate-risk pancreatic lesions pancreatic lesions are defined as: 1. Branch-duct IPMN without HGD 2. Neuroendocrine tumor \< 2 cm 3. dilation of main pancreatic duct \< 8 mm 4. Chronic pancreatitis-like change
Time frame: From year 1 to year 12 (end of at least 5 years follow up in 2032) according to the standard of care designated by GI team.
Proportion of patients undergoing screening who undergo pancreatic surgery
Proportion of patients who undergo pancreatic surgery as a result of screening test results following the Fukuoka revised guidelines for the management for high-risk lesions or surgical treatment designated by interdisciplinary medical team
Time frame: From year 1 to year 12, which is the end of at least 5 years follow up in 2032.(throughout the duration of the study)
Proportion of "low yield" pancreatic surgeries performed in screening patients
Proportion of patients who undergo "low-yield pancreatic surgery" as a result of screening test results. Low yield pancreatic surgery is defined surgery where surgical pathology does not yield high-risk pancreatic lesions. See primary outcome for definition of high-risk pancreatic lesions.
Time frame: From year 1 to year 12, which is the end of at least 5 years follow up in 2032.(throughout the duration of the study)
Proportion of screening patients who undergo non-pancreatic surgery
Proportion of patients who undergo non- pancreatic surgery as a result of screening test results.
Time frame: From year 1 to year 12 (the end of at least 5 years follow up in 2032), according to the standard of care designated by GI team
Proportion of screening patients who experience complications/adverse events of screen-related procedures
Proportion of patients who experienced any complications or adverse events due to screen-related procedures as Endoscopic Ultrasound (EUS), Magnetic resonance cholangiopancreatography (MRCP) or others that have been designated by attending in the GI department. Complications and adverse events will be aggregated to be reported as one value (complications/adverse events). Complications, defined as adverse events that emphasize direct causality between medical care and the adverse outcome or event. Adverse event, defined as an event that may or may not be preventable or result from a medical error
Time frame: From year 1 to year 12 (the end of at least 5 years follow up in 2032), according to standard of care designated by GI team
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Jul 2020 (actual). Primary completion is estimated for Dec 2032, 149 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Deaconess Medical Center →